Studies people at high risk of developing inflammatory bowel disease
Looks for risk factors in people at high risk of inflammatory bowel disease.
Key facts
- Who runs it
- Seoul National University Hospital
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- SNU IBD Cohort Study : Searching for Characterization of High Risk Populations for Developing Inflammatory Bowel Disease
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 7 Jan 2022
- Planned end
- 31 Dec 2025
- Type of study
- Observational
- Record updated
- 10 June 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people at high risk of developing inflammatory bowel disease (IBD). This includes close relatives of IBD patients, people with autoimmune diseases, and some people with stomach and bowel problems who test ASCA-positive.
- Age
- 10 years and older
- Sex
- All sexes can join.
- Disease stage
- People who do not have IBD but are at high risk of getting it: first-degree relatives of IBD patients, people with an autoimmune disease, or people with functional gastrointestinal disorders.
- Earlier treatment
- People with a treatment history of diabetes mellitus, irritable bowel syndrome or colon cancer cannot join.
- Biomarker or test result
- People with functional gastrointestinal disorders must be ASCA-positive.
Main reasons for not taking part
- Found to have inflammatory bowel disease on colonoscopy after symptoms such as 10% weight loss within 3 months, abdominal pain, blood in stool or diarrhea
- Treatment history of diabetes mellitus
- Treatment history of irritable bowel syndrome
- Treatment history of colon cancer
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- first-degree relatives of Inflammatory Bowel Disease patients
- patients who are diagnosed with autoimmune diseases
- patients with functional gastrointestinal disorders who are ASCA-positive
Who cannot take part
- Patients with symptoms such as a 10% weight loss within 3 months, abdominal pain, hematochezia, or diarrhea will undergo colonoscopy, and those diagnosed with Inflammatory Bowel Disease will be excluded
- Treatment history of Diabetes Mellitus, Irritable Bowel Syndrome, or colon cancer
Where in South Korea
- Seoul National University HospitalSeoul, South KoreaContact: KohTaking people
About the trial
What the trial wants to find out
The goal of this observational study is to investigate characteristics of individuals at high risk for developing Inflammatory Bowel Disease (IBD) in order to identify risk factors associated with its incidence.
Read full original descriptionShow less
The main question it aims to answer is:
What are the risk factors for developing Inflammatory Bowel Disease?
Researchers will compare groups at high risk for IBD to healthy populations and to patients already diagnosed with IBD.
Participants will
* undergo assessments of general demographic and clinical characteristics. * be monitored for symptoms using questionnaires administered at regular intervals. * have blood tests and stool examinations performed. In cases where participants undergo colonoscopy for routine clinical indications, gut biopsies will also be performed.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- SNU IBD Cohort Study : Searching for Characterization of High Risk Populations for Developing Inflammatory Bowel Disease (SNU PREVENT)
- Plain-language title
- Studies people at high risk of developing inflammatory bowel diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 June 2025